Medication copayment vouchers for P2Y12 inhibitors not associated with reduced major adverse cardiovascular events

Medication co-payment vouchers for P2Y12 inhibitors not associated with reduced major adverse cardiovascular events

06:00 EST 12 Jan 2019 | 2 Minute Medicine

1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI). 2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients. Evidence Rating Level: 1 (Excellent)       Study Rundown: Antiplatelet therapy, such […]
Source: 2 Minute Medicine

More From BioPortfolio on "Medication co-payment vouchers for P2Y12 inhibitors not associated with reduced major adverse cardiovascular events"